TSMC's Strong Outlook Boosts Tech Stocks, Futures Up Modestly
Stock futures are experiencing modest gains in early trading as optimism around a strong outlook from Taiwan Semiconductor Manufacturing bolsters technology sentiment and lifts semiconductor and AI-related shares. This suggests investor risk appetite is returning after recent weaker sessions. Analysts note that TSMC's robust quarterly results and plans for expanded U.S. manufacturing have injected fresh confidence into the chip sector and could support broader tech leadership even as markets await further corporate earnings.Still, broader sentiment remains mixed and cautious after a two-day losing streak for major U.S. indexes, driven by profit-taking in technology shares and concerns around banking sector pressures, including regulatory risks and proposals on credit card rate caps that have weighed on financial stocks.Currency and bond markets have also shifted in response to these cross-currents, contributing to the broader risk-on yet cautious tone.In pre-market trading, S&P 500 futures rose 0.49%, Nasdaq futures rose 1.07% and Dow futures slipped 0.07%.Check out this morning's top movers from around Wall Street, compiled by The Fly.HIGHER -Penumbraup 13% after entering into a definitive agreement under which Boston Scientificwill acquire the company in a cash and stock transaction that values Penumbra at $374 per shareSpotifyup 1% after announcing that it is raising prices for premium subscriptionsUP AFTER EARNINGS -TSMCup 5%Insteelup 5%BlackRockup 2%DOWN AFTER EARNINGS -Morgan Stanleydown 1%Goldman Sachsdown 1%LOWER -Boston Scientificdown 4% after announcing its agreement to acquire PenumbraInstacartdown 5% after Uberand Krogerannounced the launch of nearly 2,700 stores on the Uber Eats, Uber, and Postmates apps
Trade with 70% Backtested Accuracy
Analyst Views on BSX
About BSX
About the author

- Lawsuit Background: Boston Scientific Corporation (NYSE:BSX) is facing a class action lawsuit for making misleading statements during the period from July 23, 2025, to February 3, 2026, with a lead plaintiff motion deadline of May 4, 2026.
- Growth Rate Concerns: The lawsuit alleges that the growth rate of Boston Scientific's U.S. Electrophysiology (EP) segment was unsustainable and approaching a tipping point earlier than anticipated, severely impacting investor confidence in the company's future.
- Competitive Pressure: The company is experiencing new entrants in the market that are eroding its market share in U.S. Electrophysiology, thereby limiting its growth potential and increasing the risk of investor losses.
- Misleading Statements: Executives at Boston Scientific repeatedly expressed confidence in the growth trajectory of its EP division, but these positive statements are alleged to lack a reasonable basis, misleading investors about the company's business outlook.
- Conference Participation: Boston Scientific will participate in Bernstein's 42nd Annual Strategic Decisions Conference on May 27, 2026, with CEO Mike Mahoney and CMO Janar Sathananthan engaging in a 50-minute Q&A session, which is expected to enhance investor understanding of the company's strategy.
- Earnings Call: The company will host a conference call on July 29, 2026, at 8:00 AM ET to discuss financial results and business highlights for the second quarter ended June 30, thereby increasing transparency and attracting investor interest.
- Financial Results Announcement: Boston Scientific will issue a news release announcing its second-quarter 2026 financial results prior to the earnings call, ensuring that investors receive timely key information that could influence market expectations regarding the company's future performance.
- Webcast Availability: Live webcasts and replays of each event will be accessible on the company's investor website, enhancing information accessibility and ensuring that investors can stay updated on the latest company developments.
- ServiceNow Performance Review: Despite achieving a 20% revenue growth in 2022 and a 19% growth in Q1 2023, ServiceNow's stock has plummeted over 50% from its July peak, reflecting an overreaction from the market towards AI stocks, resulting in a three-year low market cap.
- Roblox Growth Slowdown: The recently implemented age verification measures have led Roblox to revise its 2023 revenue growth forecast down from 23%-29% to 20%-25%, even though last quarter's revenue reached $1.4 billion, a 39% increase, indicating short-term market pressures.
- Boston Scientific Outlook Adjustment: Boston Scientific's Watchman implant showed promising results in trials, but the unclear long-term benefits have caused a reduction in its 2026 revenue growth forecast from 10%-11% to 6.5%-8%, although analysts remain optimistic, viewing the current stock price as a buying opportunity.
- Market Sentiment Analysis: Following a strong rebound in April, the overall market has seen certain growth stocks suffer due to fluctuating market sentiment, prompting investors to carefully assess the long-term value versus short-term volatility of these stocks.
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made false and misleading statements during the class period, leading to investor losses when the company missed net income expectations for the first quarter, revealing management's concealment of unsustainable growth in its electrophysiology segment.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, demonstrating its expertise and success in this field.
- Investor Selection Advice: Investors are advised to be cautious when selecting legal counsel, avoiding inexperienced intermediaries, and ensuring that their chosen law firm has the capability to handle securities class actions to maximize potential recovery opportunities.
- Lawsuit Background: Boston Scientific Corporation is facing a class action lawsuit for alleged violations of federal securities laws, with plaintiffs being investors who purchased securities between July 23, 2025, and February 3, 2026, seeking to recover damages.
- False Statement Allegations: The complaint alleges that the company made materially false and misleading statements during the relevant period, failing to disclose that the projected growth rate for its U.S. electrophysiology segment was unsustainable, which undermined investor confidence in the company's future.
- Market Reaction: Plaintiffs claim that management's optimistic outlook for the U.S. electrophysiology division lacked a reasonable basis and failed to timely disclose competitive pressures and regulatory challenges, potentially leading to significant investor losses.
- Investor Action: Affected investors have until May 4, 2026, to request to be appointed as lead plaintiffs, and Boston Scientific investors need not worry about litigation costs, as attorney fees are typically reimbursed by the court only upon success.
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made false and misleading statements during the Class Period, concealing the true state of its U.S. Electrophysiology segment, which led to investor losses when the company's net income fell short of expectations.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its success and resource advantages in handling such cases.
- Investor Selection Advice: Investors are advised to carefully choose legal counsel and avoid working with inexperienced middlemen to ensure effective legal representation in the class action.











